Travere Therapeutics, Inc. · NASDAQ:TVTX

Travere Therapeutics — Technical Presentation (August 2024)

6 slides from Travere Therapeutics's technical presentation, August 2024

  1. Slide 1: Natural History of Idiopathic Nephrotic Syndrome: The UK National RaDaR Cohort

    Natural History of Idiopathic Nephrotic Syndrome: The UK National RaDaR Idiopathic Nephrotic Syndrome Cohort David Pitcher,1 Jonathan Barratt,2 Fiona Braddon,1 Wu Gong,3 Bruce Hendry,3 Alex Mercer,4 Kate Osmaston,1 Retha Steenkamp,1 A. Neil Turner,5 Daniel P. Gale,1,6 Moin A. Saleem7 1UK Kidney Asso

  2. Slide 2: Introduction and Methods

    Introduction and Methods • Idiopathic nephrotic syndrome (INS) is an important class of proteinuric kidney disease leading to kidney failure (KF) • Here we describe the natural history of INS, including genetic nephrotic syndrome, using the UK National Registry of Rare Kidney Disease (RaDaR) INS Coh

  3. Slide 3: Characteristics at Disease Onset

    Characteristics at Disease Onset • In total, 4066 patients (including 1599 children [39%]) were included, with a median age at disease onset* of 28 years INS with no INS with a Biopsy-proven Biopsy-proven MCD progressing genetic or biopsy Characteristic genetic diagnosis FSGS MCD to FSGS diagnosis (

  4. Slide 4: Total Time-Averaged Proteinuria and Annual Rate of eGFR Loss

    Proteinuria and Annual Rate of eGFR Loss Time-Averaged Proteinuria (All Ages) Annual Rate of eGFR Loss (All Ages) 25 0 ‒2.3 (9.9) ‒3.3 (15.1) (SD), mL/min/1.73 m2/year proteinuria, mean (SD), g/g eGFR total slope, mean ‒5 ‒6.5 (15.6) 20 ‒8.1 (14.0) Total time-averaged 20.3 (28) ‒10 15 ‒15 10 ‒20 5 6

  5. Slide 5: Time to Kidney Failure or Death

    Time to Kidney Failure or Death • Over a median follow-up duration of 8.2 years, KF or death occurred in 30% of patients • Survival probability was generally poor for patients with INS, particularly those with a genetic diagnosis or biopsy-proven FSGS Survival Probability Over Time Log-rank P<0.0001

  6. Slide 6: Conclusion

    Conclusion • In a large cohort of patients with INS, 10-year kidney survival/death rates ranged from 29% for genetic INS to 58% for biopsy-proven FSGS and 87% for MCD • The disease burden in these populations highlight an unmet need for effective treatments for patients with nephrotic syndrome and F

Travere Therapeutics — Technical Presentation (August 2024) on 6ix